2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-W031620
    VGSCs-IN-1 1204296-79-6 98%
    VGSCs-IN-1 (compound 14), a 2-piperazine analog of Riluzole (HY-B0211), is a human voltage-gated sodium channels (VGSCs) inhibitor. VGSCs-IN-1 shows great Nav1.4 blocking activity. VGSCs-IN-1 has a pKa of 7.6 and a cLog P of 2.4. VGSCs-IN-1 can be used for cell excitability disorders research.
    VGSCs-IN-1
  • HY-W033027
    BGT1-IN-1 406947-32-8 98%
    BGT1-IN-1 (compound 9) is a potent BGT1 inhibitor with IC50 value of 13.9, 58.3 µM for hBGT1, GAT3, respectively. BGT1-IN-1 shows no cytotoxic. BGT1-IN-1 shows neuroprotective activity.
    BGT1-IN-1
  • HY-W035384
    MAO-B ligand-1 1010879-39-6 98%
    MAO-B ligand-1 is a MAO-B inhibitor, with IC50 values of 22.57 and 3.83 nM for hMAO-A and hMAO-B, respectively.
    MAO-B ligand-1
  • HY-W035404
    1-(1,3-Diphenylpropan-2-yl)pyrrolidine hydrochloride 102009-66-5 98%
    1-(1,3-Diphenylpropan-2-yl)pyrrolidine hydrochloride is structurally similar to known dissociative anesthetics.
    1-(1,3-Diphenylpropan-2-yl)pyrrolidine hydrochloride
  • HY-W049335
    6,9-Dichloro-1,2,3,4-tetrahydroacridine 5396-25-8 98%
    6,9-Dichloro-1,2,3,4-tetrahydroacridine (compound 26) is an intermediate for the synthesis of acetylcholinesterase (AChE) inhibitors, which can be used in the study of Alzheimer's disease.
    6,9-Dichloro-1,2,3,4-tetrahydroacridine
  • HY-W049881
    9-Methyl-β-carboline 2521-07-5
    9-Methyl-β-carboline is a cognitive enhancer with neuroprotective, neurorestorative and anti-inflammatory properties. The behavioral effects of 9-Methyl-β-carboline may be related to the stimulation of hippocampal dopamine levels and dendritic and synaptic proliferation.
    9-Methyl-β-carboline
  • HY-W052248
    RU 23686 free base 52157-82-1 98%
    RU 23686 free base is a piperidinylindole derivative. RU 23686 free base can be used to investigate the extent to which different neurotransmitters by the interaction with pharmacological agents.
    RU 23686 free base
  • HY-W061043
    DOV-216,303 86215-36-3 98%
    DOV-216,303 is an antidepressant compound. DOV-216,303 inhibits the reuptake of norepinephrine (NE), serotonin (5‐HT), and dopamine (DA), with IC50 values of 14 nM, 20 nM and 78 nM for hSERT, hNET and hDAT, respectively. DOV-216,303 increases monoamine release in the prefrontal cortex of olfactory bulbectomized (OBX) rats.
    DOV-216,303
  • HY-W072274
    (S)-Desoxy-D2PM hydrochloride 188398-87-0 98%
    (S)-Desoxy-D2PM ((S)-2-Diphenylmethylpyrrolidine) hydrochloride is a neuroactive compound.
    (S)-Desoxy-D2PM hydrochloride
  • HY-W083026
    (E)-CHBO4 126473-61-8
    (E)-CHBO4 is a MAO-B inhibitor, with an IC50 of 0.023 μM, and can be used for research on the treatment of Parkinson's disease.
    (E)-CHBO4
  • HY-W083062
    hMAO-B-IN-5 358343-63-2 99.66%
    hMAO-B-IN-5 (Compound B15) is a potent, selective and reversible human monoamine oxidase-B (hMAO-B) inhibitor with an IC50 of 120 nM and a Ki of 33 nM. hMAO-B-IN-5 can be used in the research of neurodegenerative diseases.
    hMAO-B-IN-5
  • HY-W097106
    (S)-3-N-Cbz-Amino-succinimide 60846-91-5 98%
    (S)-3-N-Cbz-Amino-succinimide (Compound 1d) is an antiepileptic agent that can inhibit pentylenetetrazole (PTZ) and maximal electroshock (MES)-induced tonic convulsions in mice.
    (S)-3-N-Cbz-Amino-succinimide
  • HY-W097625
    6-Methoxyflavone 26964-24-9 99.87%
    6-Methoxyflavone is a methoxyflavone that can be isolated from Pimelea simplex F. Muell. and P. decora Domin.. 6-Methoxyflavone exhibits anti-inflammatory effects and neuropathic pain relieving properties in chemotherapy-induced peripheral neuropathy (CIPN). 6-Methoxyflavone can be used in the research of nephritis.
    6-Methoxyflavone
  • HY-W099757
    (±)-Coniine hydrochloride 15991-59-0 ≥98.0%
    (±)-Coniine hydrochloride (2-Propylpiperidine hydrochloride) is a potent nAChR agonist with an EC50 value of 0.3 mM. (±)-Coniine hydrochloride shows acute toxicity with an LD50 value of 7.7 mg/kg.
    (±)-Coniine hydrochloride
  • HY-W100784
    2,6-Dimethylphenylthiourea 6396-76-5 98%
    2,6-Dimethylphenylthiourea is a Xylazine metabolite. Xylazine is the first and most widely used α2-agonist.
    2,6-Dimethylphenylthiourea
  • HY-W106057
    11β-HSD1-IN-7 728-86-9 99.73%
    11β-HSD1-IN-7 (compound c10a) is a 11β HSD1 inhibitor with an IC50 value of 1.9 μM for human 11β HSD1. 11β-HSD1-IN-7 can be used for the research of diabetes and cognitive decline.
    11β-HSD1-IN-7
  • HY-W116433
    SK609 144887-95-6 98%
    SK609 is a selective dopamine D3 receptor agonist with activity that improves dopamine and norepinephrine levels in the cerebral cortex. SK609 has been successfully used to suppress dyskinesias in Parkinson's disease models and alleviated muscle twitches induced by L-dopa. SK609 improved performance in sustained attention tasks by significantly reducing misses and false alarms. SK609 may provide an inhibitory option for suppressing movement and cognitive impairment in patients with Parkinson's disease.
    SK609
  • HY-W117986
    Aβ aggregation-IN-1 352525-91-8 99.92%
    Aβ aggregation-IN-1 (Compound 1b) is an amyloid-beta precursor protein inhibitor. Aβ aggregation-IN-1 inhibits amyloid-beta aggregation and disaggregation of fibrillogenesis with IC50 values of 3.92 and 7.19 M, respectively. Aβ aggregation-IN-1 also inhibits malondialdehyde formation, augments the intracellular reduced glutathione (GSH) levals and inhibits caspase 3 in neuronal cells.
    Aβ aggregation-IN-1
  • HY-W130232
    Diformylphloroglucinol 4396-13-8 99.58%
    Diformylphloroglucinol is an acylphloroglucinol compound that can be used in the synthesis of Psiguadial B. Psiguadial B is a neuroprotective agent.
    Diformylphloroglucinol
  • HY-W165085
    1,10-Bis(pyridinium)decane 6266-40-6 99.66%
    1,10-Bis(pyridinium)decane (Decamethylenebispyridinium dibromide), a biscationic compound, is an acetylcholinesterase (AchE) inhibitor with an IC50 of 25.8 nM.
    1,10-Bis(pyridinium)decane
Cat. No. Product Name / Synonyms Application Reactivity